Vertex Pharmaceuticals (VRTX) Capital Expenditures (2009 - 2026)

Vertex Pharmaceuticals' Capital Expenditures history runs 18 years deep, the most recent figure standing at $133.4 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 227.76% year-over-year to $133.4 million; the TTM figure through Mar 2026 stood at $530.3 million (up 96.41% YoY), while the FY2025 annual figure was $437.6 million, up 46.99% from the prior year.
• Capital Expenditures for Q1 2026 stood at $133.4 million, down from $149.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $149.4 million in Q4 2025, with the low at $33.6 million in Q4 2022.
• The 5-year median for Capital Expenditures is $63.6 million (2022), against an average of $74.9 million.
• The sharpest annual moves came in 2022 and 2026: Capital Expenditures sank 45.63% in 2022, then surged 227.76% in 2026.
• Vertex Pharmaceuticals' Capital Expenditures stood at $33.6 million in 2022, then soared by 72.92% to $58.1 million in 2023, then jumped by 59.38% to $92.6 million in 2024, then jumped by 61.34% to $149.4 million in 2025, then retreated by 10.71% to $133.4 million in 2026.
• Business Quant data shows VRTX's Capital Expenditures at $133.4 million in Q1 2026, $149.4 million in Q4 2025, and $101.8 million in Q3 2025.